tiprankstipranks
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
US Market
AVBP
ArriVent BioPharma, Inc.
RESEARCH TOOLSreports
Want to see AVBP full AI Analyst Report?

ArriVent BioPharma, Inc. (AVBP) Stock News & Sentiment

81 Followers
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
Premium
Ratings
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
10d ago
AVBP
ArriVent BioPharma Updates At-The-Market Equity Offering Program
Premium
Company Announcements
ArriVent BioPharma Updates At-The-Market Equity Offering Program
11d ago
8K
AVBP
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
11d ago
AVBP
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
25d ago
AVBP
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
Premium
Company Announcements
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
2M ago
8K
AVBP
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
Premium
Ratings
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
2M ago
AVBP
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
Premium
Ratings
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
4M ago
AVBP
More AVBP News >

AVBP News on the Web

LifeSci Capital Remains a Buy on ArriVent BioPharma, Inc. (AVBP)
TipRanks News
Bullish
ArriVent Biopharma price target lowered to $43 from $45 at Citi
TipRanks News
Bullish
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Oppenheimer
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Hims & Hers Health (HIMS) and ArriVent BioPharma, Inc. (AVBP)
TipRanks News
Bullish
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
TipRanks News
Bullish
ArriVent BioPharma Updates At-The-Market Equity Offering Program
TipRanks News
Neutral
ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
TipRanks News
Bullish
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
AVBP
Sector Average
Media Buzz
This Week2 articles
Weekly Average3 articles
News Sentiment
This Week99%
Sector Average79%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is AVBP’s Media Buzz Sentiment?
2 articles about AVBP were published this week. In an average week, 3 articles are published.
    What is AVBP’s weekly average amount of articles?
    In an average week, 3 articles about AVBP are published.
      What is AVBP’s News Sentiment?
      99% of articles about AVBP were positive this week, compared to its sector average of 79%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        JUNSJupiter Neurosciences, Inc.
        Showing the stocks with the most bullish news sentiment over the past week